🔎 Trials Near Me

Gara Jalqabaatti › Burkitt Lymphoma › Ohio › Cincinnati

Qorannoo klinikaalii Burkitt Lymphoma Cincinnati, OH keessatti

Qorannoo 13 Burkitt Lymphoma f Cincinnati fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Namoota walitti qabaa jiraSadarkaa 3
  • Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
Umuriin 1 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07223021

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Namoota walitti qabaa jiraSadarkaa 1
  • Cincinnati Children's Hospital, Cincinnati
Umuriin 0 hanga 18 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06173518

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Namoota walitti qabaa jiraSadarkaa 3
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · Miili 15 fagaatti
Umuriin 18 hanga 39 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03150693

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umuriin 0 hanga 38 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06131801

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Namoota walitti qabaa jiraSadarkaa 2
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Namoota walitti qabaa jiraSadarkaa 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
365 Days · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Namoota walitti qabaa jiraSadarkaa 3
  • University of Cincinnati Medical Center, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Namoota walitti qabaa jiraSadarkaa 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umuriin 1 hanga 30 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Namoota walitti qabaa jiraSadarkaa 3
  • Cincinnati Children's Hospital Medical Center, Cincinnati
365 Days – 25 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Namoota walitti qabaa jiraSadarkaa 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umuriin 7 hanga 25 · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT05082519

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Namoota walitti qabaa jiraSadarkaa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umuriin 1 hanga 39 · Saalaa hunda · Haaromfame 18-Gur-2026 · NCT06863259

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Namoota walitti qabaa jiraSadarkaa 1
  • University of Cincinnati, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Sad-2024 · NCT06034275

Qorannoo Burkitt Lymphoma magaalota biroo keessatti

Qorannoo biroo Cincinnati keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.